Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders -
- 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment -
- Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months -
- Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Mark R. Barakat, M.D. -
Clearside will host a webcast and conference call with accompanying slides today at 8:30 a.m. ET, including comments by management and retinal expert, Dr. Mark R. Barakat. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (888) 506-0062 (domestic) or (973) 528-0011 (international) and entering conference code: 676850.
https://finance.yahoo.com/news/clearside-biomedical-announces-positive-6-120500797.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.